Loading…
Nephrocare Health Services (NEPHROPLUS)₹620.05+0.10%Healthcare Service Provider
In the Jun 2026 quarter (consolidated), Nephrocare Health Services reported sales of ₹282 Cr, up 23.7% from Jun 2025, and net profit of ₹32.02 Cr, up 33.4% year on year. For the year to Mar 2026, sales were ₹998 Cr and net profit ₹76.95 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|
| Sales | 197 | 219 | 228 | 246 | 260 | 266 | 282 |
| Expenses | 153 | 168 | 180 | 182 | 199 | 215 | 221 |
| Operating Profit | 43.96 | 51.02 | 47.99 | 63.98 | 60.98 | 50.98 | 59.96 |
| OPM % | 21.9% | 23.0% | 21.0% | 26.0% | 23.0% | 19.0% | 20.9% |
| Other Income | 5.01 | 4.01 | 7.01 | 4.01 | 3.01 | 12.02 | 7.01 |
| Interest | 5.01 | 6.01 | 6.01 | 45.10 | 6.01 | 3.01 | 2.01 |
| Depreciation | 18.01 | 19.01 | 20.03 | 23.02 | 22.01 | 26.03 | 24.99 |
| Profit before tax | 26.03 | 30.02 | 29.01 | −1.01 | 36.03 | 33.02 | 41.04 |
| Tax % | 24.0% | 17.0% | 17.0% | 1,427.0% | 11.0% | 9.0% | 22.0% |
| Net Profit | 20.01 | 24.98 | 24.01 | −8.99 | 31.98 | 29.98 | 32.02 |
| EPS (Rs) | 96.82 | 119.67 | 13.14 | −5.25 | 3.22 | 3.04 | 3.20 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|
| Sales | 286 | 318 | 436 | 565 | 755 | 998 | 1,053 |
| Expenses | 248 | 302 | 389 | 465 | 589 | 774 | 817 |
| Operating Profit | 37.01 | 16.01 | 48.99 | 101 | 167 | 225 | 236 |
| OPM % | 12.9% | 5.0% | 11.0% | 18.0% | 22.0% | 23.0% | 22.4% |
| Other Income | 5.01 | 10.02 | 6.01 | 8.01 | 14.01 | 23.04 | 26.05 |
| Interest | 7.01 | 10.02 | 16.03 | 20.04 | 21.03 | 60.17 | 56.13 |
| Depreciation | 34.04 | 41.99 | 47.01 | 56.03 | 72.01 | 91.11 | 96.05 |
| Profit before tax | 1.01 | −27.01 | −9.01 | 33.03 | 87.07 | 97.05 | 109 |
| Tax % | 31.0% | −21.0% | 37.0% | −6.0% | 23.0% | 21.0% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.01 | — |
| Net Profit | 0.99 | −20.99 | −12.01 | 35.01 | 66.96 | 76.95 | 84.99 |
| EPS (Rs) | 3.41 | −107.23 | −58.89 | 170.35 | 322.88 | 7.69 | 4.21 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 1.99 | 1.99 | 1.99 | 1.99 | 1.99 | 19.94 |
| Reserves | 244 | 390 | 383 | 408 | 577 | 1,093 |
| Borrowings | 140 | 119 | 200 | 270 | 261 | 79.82 |
| Other Liabilities | 42.02 | 59.24 | 80.92 | 124 | 153 | 272 |
| Total Liabilities | 427 | 570 | 665 | 804 | 992 | 1,465 |
| Fixed Assets | 192 | 205 | 239 | 356 | 395 | 516 |
| CWIP | 2.01 | 43.16 | 34.13 | 1.01 | 6.02 | 6.02 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 51.21 | 179 |
| Other Assets | 233 | 321 | 392 | 448 | 540 | 765 |
| Inventories | 15.95 | 14.94 | 25.91 | 25.88 | 26.91 | 32.86 |
| Trade receivables | 78.74 | 107 | 159 | 203 | 265 | 316 |
| Cash & equivalents | 65.25 | 143 | 127 | 61.22 | 156 | 256 |
| Total Assets | 427 | 570 | 665 | 804 | 992 | 1,465 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Cash from operating activity | 31.86 | 13.96 | 10.96 | 71.71 | 135 | 232 |
| Cash from investing activity | −62.18 | −130 | −76.21 | −52.11 | −125 | −393 |
| Cash from financing activity | 36.11 | 121 | 60.17 | 27.10 | 54.20 | 157 |
| Net cash flow | 5.01 | 6.01 | −4.01 | 47.10 | 65.16 | −2.01 |
| Capex | 61.01 | 78.97 | 73.99 | 79.93 | 101 | 119 |
| Free cash flow | −28.96 | −63.89 | −61.87 | −7.99 | 34.94 | 113 |
| CFO / OP % | 49.0% | 119.0% | 14.0% | 80.0% | 82.0% | 116.0% |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor days | 100 | 122 | 131 | 130 | 128 | 115 |
| Inventory days | 65 | 50 | 67 | — | — | — |
| Days payable | 55 | 69 | 62 | — | — | — |
| Cash conversion cycle | 110 | 103 | 137 | 131 | 129 | 116 |
| Working capital days | 26 | 55 | 19 | 56 | 27 | 42 |
| ROCE % | — | −4.0% | 1.0% | 8.0% | 14.0% | 15.0% |
For the Jun 2026 quarter, Nephrocare Health Services reported sales of ₹282 Cr, up 23.7% year on year and net profit of ₹32.02 Cr, up 33.4% year on year. The operating margin was 20.9%.
Nephrocare Health Services' sales for the year to Mar 2026 were ₹998 Cr; over the last twelve months they were ₹1,053 Cr.
Net profit for the year to Mar 2026 was ₹76.95 Cr, and ₹84.99 Cr over the last twelve months. Earnings per share over the same trailing period were ₹4.21.
Nephrocare Health Services reported borrowings of ₹79.82 Cr at Mar 2026, against cash and equivalents of ₹256 Cr.
Cash from operations was ₹232 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹113 Cr.